BILL ANALYSIS

S1929

BULLISH

SEPSIS Act

S1929 (SEPSIS Act) has been assessed with a bullish outlook for investors. This legislation directly affects $BDX and Thermo Fisher Scientific ($TMO). The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

bullish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

The SEPSIS Act is an early-stage authorization bill that has not progressed past committee referral in over 10 months — passage probability is low in the current Congress.

No funding is appropriated in the bill; actual spending requires a separate appropriations bill that does not yet exist.

If funded, diagnostic companies (BDX, TMO, DGX, LH) and hospital monitoring firms (GEHC, ABT) would benefit, but the market has not priced in any legislative catalyst — all tickers are trading near 52-week lows on unrelated market pressure.

How S1929 Affects the Market

The SEPSIS Act in its current form provides no material catalyst for healthcare stocks. Real market data shows BDX, TMO, DGX, LH, ABT, and GEHC are all in sharp downtrends over the past 7 and 30 days, driven by broader market factors (likely macro headwinds, sector rotation, or company-specific issues) rather than legislative sentiment. BDX at $145.31 has declined 6.16% in the past week and is 22% below its 52-week high. TMO at $466.26 has lost over $60/share since April 16. GEHC at $59.49 has dropped nearly 15% in a single week. These are not stocks showing anticipation of a sepsis-related catalyst. Investors should monitor committee activity and appropriations language in FY2027 budget cycles for potential entry points, but the current bill does not justify allocation to these names.

Bill Details

Metric	Value
Bill Number	S1929
Market Sentiment	bullish
Event Date	June 3, 2025
Affected Sectors	Healthcare
Affected Stocks	$BDX, Thermo Fisher Scientific ($TMO)
Source	View on Congress.gov →

Summary

The SEPSIS Act (S.1929) is an early-stage authorization bill that would create federal programs for sepsis research, education, and data collection. It authorizes but does not appropriate funding, and with only 6 cosponsors and referral to committee in June 2025, passage remains uncertain. Real market data shows all four diagnostic/lab stocks have declined 1-6% in the past week and 2-10% over 30 days, reflecting broader market pressure on healthcare despite the legislative catalyst.

Full AI Market Analysis

1) What happened: The SEPSIS Act (S.1929) was introduced in the Senate on June 3, 2025, by Majority Leader Schumer (D-NY) with 6 cosponsors. It was read twice and referred to the Committee on Health, Education, Labor, and Pensions. An identical companion bill (HR7116) was introduced in the House and referred to the Energy and Commerce Committee. The bill is in early legislative stages and has not progressed past committee referral in over 10 months. 2) The money trail: This is an authorization bill — it does not appropriate any specific dollar amount. Section 3 of the bill directs the CDC to maintain a sepsis team for education, data collection, and best practice dissemination. No funding level is specified. Actual spending would require a separate appropriations bill, which has not been introduced. The bill's findings reference the high cost of sepsis treatment ($38 billion annually per CMS data) but do not translate this into authorized spending. 3) Structural winners and losers: If funded, diagnostic companies would benefit from increased hospital protocol adoption. BDX ($145.31) provides blood culture and rapid diagnostic platforms used in hospitals. TMO ($466.26) supplies research equipment for sepsis biomarker discovery. DGX ($189.32) and LH ($257.14) are positioned for outpatient testing volume increases. ABT ($91.33) has sepsis-related diagnostics (Alinity i, i-STAT) but is more diversified. GEHC ($59.49) provides hospital monitoring equipment that could see demand from protocol-driven sepsis management. All remain early-stage beneficiaries contingent on future appropriations. 4) Real market data context: As of April 29, 2026, all relevant stocks are trading near or at their 52-week lows. BDX at $145.31 (52wk range $127.59-$187.35) is down 6.16% in the past week. TMO at $466.26 is down 0.09% weekly but sits near its 52-week low of $385.46 — a steep drop from recent close of $526.60 on April 17. DGX at $189.32 is down 5.12% weekly and approaching its 52-week low of $164.65. ABT at $91.33 is essentially at its 52-week low of $90.72 and down 10.36% over 30 days. GEHC at $59.49 has crashed 14.88% in the past week and is at its 52-week low. The broad market sell-off in healthcare names is unrelated to the SEPSIS Act, which has not progressed. 5) Timeline: The bill is stalled. With one action (introduction and referral) occurring 10 months ago and no hearings, markups, or floor votes, passage in the 119th Congress is unlikely unless the bill gains new sponsors or committee attention. Reintroduction in the 120th Congress (2027-2029) is possible but requires restarting the legislative process.